MediWound (Nasdaq: MDWD) will release its second quarter 2026 financial results for the period ended June 30, 2026 on Thursday, August 13, 2026, followed by a management-hosted conference call and live webcast at 8:30 a.m. Eastern Time to discuss results and provide a corporate update.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
The prior earnings-date announcements produced -0.58% and +0.88% 24-hour reactions, while recent ins...
Analysis
The prior earnings-date announcements produced -0.58% and +0.88% 24-hour reactions, while recent insider activity was Net Buying. The August release will provide the substantive update; execution and results remain the key items to watch.
Scheduled Q4 and full-year 2025 results release with management conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Tag-matched earnings-date announcements produced mixed reactions, with an average move of 0.15%.
Key Terms
biologic, eschar, debridement, fda-approved
4 terms
biologicmedical
"The company’s FDA-approved biologic, NexoBrid®, is indicated"
A biologic is a medicine made from living cells or organisms—such as proteins, antibodies or vaccines—rather than being chemically synthesized. Investors watch biologics closely because they are expensive and complex to develop and manufacture, often enjoy strong market pricing and protections, and face unique regulatory and supply risks; think of them like handcrafted specialty goods versus mass-produced items with higher potential reward and higher production risk.
escharmedical
"for the enzymatic removal of eschar in thermal burns"
A dry, dark scab of dead tissue that forms over a wound or ulcer when skin cells and blood supply have been damaged; it’s the crusty layer doctors inspect to judge healing or infection. For investors, eschar matters in healthcare contexts because its presence, size, or changes can signal how well a treatment, device or wound-care product is working, or indicate complications that may affect clinical outcomes and regulatory reviews.
debridementmedical
"investigational therapy for the debridement of chronic wounds"
Debridement is the medical removal of dead, infected, or damaged tissue and foreign material from a wound to promote healing, similar to pruning dead branches so new growth can flourish. For investors, it matters because how debridement is performed — by drugs, devices, dressings, or procedures — affects clinical outcomes, product demand, reimbursement decisions, regulatory approval pathways, and the financial prospects of companies offering those solutions.
fda-approvedregulatory
"The company’s FDA-approved biologic, NexoBrid®"
FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.
MediWound to Report Second Quarter 2026 Financial Results
Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time
YAVNE, Israel, July 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026.
On the same day, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the financial results and provide a corporate update.
To access the call, participants should dial the applicable telephone number above at least five minutes prior to the start of the call. A webcast replay will be available in the Investor Relations section of the MediWound website.
About MediWound
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The company’s FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx®, is an investigational therapy for the debridement of chronic wounds, with the potential to become a new standard of care in wound management.
When will MediWound (MDWD) report its Q2 2026 financial results?
MediWound will report its Q2 2026 financial results on Thursday, August 13, 2026. According to MediWound, the release covers the quarter ended June 30, 2026 and will be followed by a conference call and live webcast the same morning.
What time is MediWound's Q2 2026 earnings conference call on August 13, 2026?
MediWound’s Q2 2026 earnings conference call starts at 8:30 a.m. Eastern Time on August 13, 2026. According to MediWound, management will discuss financial results and provide a corporate update during the call and simultaneous live webcast.
How can investors join the MediWound (MDWD) Q2 2026 earnings call by phone?
Investors can join by dialing 1-844-676-8833 toll-free in the U.S., 1-80-921-2373 in Israel, or 1-412-634-6869 internationally. According to MediWound, participants should call at least five minutes before the 8:30 a.m. Eastern Time start.
Will a replay of MediWound's Q2 2026 earnings webcast be available for MDWD shareholders?
Yes, a replay of the Q2 2026 webcast will be available after the event. According to MediWound, investors can access the replay through the Investor Relations section of the company’s website following the August 13, 2026 conference call and webcast.
What products and pipeline does MediWound (MDWD) highlight in its July 29, 2026 update?
MediWound highlights NexoBrid, an FDA-approved biologic for enzymatic removal of eschar in thermal burns, and EscharEx, an investigational debridement therapy for chronic wounds. According to MediWound, NexoBrid is marketed in the U.S., EU, Japan, and additional markets.
